A2 Biotherapeutics, an Agoura Hills, CA-based clinical-stage cell therapy company developing logic-gated cell therapies to selectively target tumor cells and protect normal cells, raised $80M in Series C funding.
Backers included The Column Group and Samsara BioCapital.
The company intends to use the funds for three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod™ platform technology.
Led by Jim Robinson, chief executive officer, A2 Bio has provided a precision-targeting cellular system, the Tmod™ platform, that incorporates two receptors, an activator and a blocker, to aim the armaments of immune cells directly at tumors to differentiate tumors from normal tissues. The activator recognizes antigens on tumor cells that trigger their destruction, while the blocker recognizes antigens on normal cells that protect them. This new blocker technology enables precise, personalized and effective T cell targeting.
The company is currently conducting two seamless phase 1/2 clinical studies: EVEREST-1 studying A2B530 for pancreatic, lung and colorectal cancers by targeting carcinoembryonic antigen (CEA); and EVEREST-2 studying A2B694 for pancreatic, ovarian, lung, colorectal and mesothelioma cancers by targeting mesothelin (MSLN).
FinSMEs
09/01/2025